Reactive Group-based Cell Surface Metabolic Oligosaccharide Engineering Service

Reactive Group-based Cell Surface Metabolic Oligosaccharide Engineering Service

Biological Roles of Reactive Group-based Cell Surface Metabolic Oligosaccharide Engineering (MOE)

MOE uses unnatural analogs instead of natural sugars to decorate cell surfaces with reactive functional groups, including hydroxyl, ketone, thiol, azide, alkene, cyclopropane, and cyclooctyne. These motifs are small enough to target a variety of biomolecules in cells and can be selectively detected via biocompatible cycloadditions. This approach enables adhesive transport of active substances as well as midway regulation of cellular metabolism.

Fig.1 Schematic representation of NK cells modified with antibodies. (Wang, et al., 2021) Fig.1 Schematic representation of NK cells modified with antibodies. (Wang, et al., 2021)

Reactive Group-based Cell Surface MOE Service at CD BioGlyco

Efficient MOE reagents are introduced into glycoproteins by cellular biosynthetic mechanisms and can be localized by bioorthogonal chemistry. At CD BioGlyco, we provide several active reagents to label cell surface oligosaccharides. At the same time, we also provide subsequent detection and expression services.

  • Cell culture service
    We provide various cell lines according to the client's needs, e.g., Caco-2, HT29-MTX-E12, GALE, etc. Cells are incubated 24h before treatment (37°C, 5% CO2).
  • Cell surface metabolic oligosaccharide labeling service
    We insert active groups on the cell surface by metabolic glycan labeling technology. Modifications include ketones, thiols, azides, alkynes, alkenes, isonitriles, and cyclopropenes. Furthermore, we offer labeling efficiency and cellular viability analysis services.
  • Other services
    We provide cytotoxicity assays, imaging observations-confocal laser scanning microscopy, flow cytometry, characterization of the cell lines using mucous staining, and quantitative image analysis services.

Fig.2 Schematic representation of cell surface MOE services based on reactive moieties. (CD BioGlyco)Fig.2 Schematic representation of cell surface MOE services based on reactive moieties. (CD BioGlyco)

Publication

Paper Title: Equipping natural killer cells with cetuximab through metabolic glycoengineering and bioorthogonal reaction for targeted treatment of KRAS mutant colorectal cancer

Technology: Metabolic glycoengineering and bioorthogonal reaction

Journal: ACS Chemical Biology

IF: 4.643

Published: 2021

Results: Azide groups were introduced onto the surface of natural killer (NK)-92 cells through metabolic glycoengineering. The engineered NK92-N3 cells were successfully conjugated with alkyne-functionalized antibodies. In vivo, experiments showed that NK92-Cetuximab could accumulate and infiltrate the tumor tissues, significantly inhibiting tumor growth.

Fig.3 Schematic representation of cell surface glycoengineering coupling and mouse model construction. (Wang, et al., 2021)Fig.3 Schematic representation of cell surface glycoengineering coupling and mouse model construction. (Wang, et al., 2021)

Applications

  • Reactive group-based cell surface MOE provides new ways to design and characterize metabolic glycan engineering systems for drug delivery and tissue engineering applications.
  • Targeting active group functionalized probes to intestinal tissues for drug delivery applications using MOE.
  • Efficient MOE reagents serve as an anchor point for quick and easy point-and-click functionalization.

CD BioGlyco has a Glycoengineering Platform to provide clients with a high-quality Cell Surface Metabolic Oligosaccharide Engineering Service (MOE). Our team of talented professionals customizes the service process to meet the needs of our clients.Please feel free to contact us.

References

  1. Tomás, R.M.F.; et al. Engineering cell surfaces by covalent grafting of synthetic polymers to metabolically-labeled glycans. ACS Macro Lett. 2018, 7(11): 1289-1294.
  2. Wang, X.; et al. Equipping natural killer cells with Cetuximab through metabolic glycoengineering and bioorthogonal reaction for targeted treatment of KRAS mutant colorectal cancer. ACS Chem Biol. 2021, 16(4): 724-730.
  3. Gutmann, M.; et al. Metabolic glycoengineering of cell-derived matrices and cell surfaces: a combination of key principles and step-by-step procedures. ACS Biomater Sci Eng. 2019, 5(1): 215-233.
  4. Lam, Y.Y.; et al. Systematic investigation of metabolic oligosaccharide engineering efficiency in intestinal cells using a dibenzocyclooctyne-monosaccharide conjugate. Chembiochem. 2023, 24(12): e202300144.
  5. Cioce, A.; et al. Optimization of metabolic oligosaccharide engineering with Ac4GalNAlk and Ac4GlcNAlk by an engineered pyrophosphorylase. ACS Chem Biol. 2021, 16(10): 1961-1967.
This service is for Research Use Only, not intended for any clinical use.

Christmas 2024

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0